tiprankstipranks
Patrys Limited Reports Progress and Potential
Company Announcements

Patrys Limited Reports Progress and Potential

Patrys Limited (AU:PAB) has released an update.

Don't Miss Our Christmas Offers:

Patrys Limited has completed a GMP production run of its therapeutic antibody PAT-DX1, with specification testing expected to conclude by July 2024. The company has also presented promising preclinical data suggesting its deoxymabs could be effective in treating vasculitis and other autoimmune diseases. As of June 30, 2024, Patrys reported a cash balance of $2.2 million, with ongoing research and development activities.

For further insights into AU:PAB stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Australian Auto-Generated NewsdeskPatrys Limited Strengthened by R&D Tax Incentive
TipRanks Australian Auto-Generated NewsdeskPatrys Limited AGM Resolutions Successfully Passed
TipRanks Australian Auto-Generated NewsdeskPatrys Limited Shifts Focus to Promising PAT-DX3 Development
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App